Trials / Completed
CompletedNCT03669367
EFFECTS OF ABATACEPT on the Progression to Rheumatoid Arthritis(PALABA Study)
EFFECTS OF ABATACEPT ON THE PROGRESSION TO RHEUMATOID ARTHRITIS IN PATIENTS WITH PALINDROMIC RHEUMATISM (PALABA)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this trial is to test the hypothesis that abatacept can reduce the progression of rheumatoid arthritis in ACPA+ or RF+ patients with palindromic rheumatism compared with patients treated with hydroxychloroquine.
Detailed description
The main objective of this trial is to test the hypothesis that abatacept can reduce the progression of rheumatoid arthritis in ACPA+ or RF+ patients with palindromic rheumatism compared with patients treated with hydroxychloroquine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abatacept Injection | Abatacept subcutaneous in monotherapy 125 mg/week during the first year (12 months). Abtacept subcutaneus in monotherapy 125 mg/2weeks during the second year. |
| DRUG | hydroxycloroquina | oral hydroxycloroquina 5 mg/Kg/day for 2 years (0-48 months) |
Timeline
- Start date
- 2019-06-03
- Primary completion
- 2022-06-30
- Completion
- 2024-09-30
- First posted
- 2018-09-13
- Last updated
- 2025-02-26
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT03669367. Inclusion in this directory is not an endorsement.